Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... THE WOODLANDS, Texas, Dec. 7, 2010 Community-based oncology practices ... iKnowMed PM. iKnowMed PM is offered by US Oncology, ... accessible via the Internet and customizable for community-based oncology practices. ... and can interface with a variety of other EHRs already ...
... Dec. 7, 2010 MedAvante, Inc., the leader in ... disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized ... Cipher recently announced the completion of the ... every patient is interviewed by a qualified MedAvante mental ...
Cached Medicine Technology:Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 2Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 3Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 4Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study 2Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study 3
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health news: Nearly two-thirds ... half your grains whole,” with the majority of Americans eating more whole grains than ... (WGC) released these findings and others from the 2015 Whole Grains Consumer Insights ...
(Date:8/31/2015)... ... 2015 , ... Now through October 31st, the National Ovarian ... on a digital screen projected above New York’s Times Square, on the 1500 ... awareness of the symptoms of ovarian cancer, and earlier conversations with doctors. This ...
(Date:8/31/2015)... ... August 31, 2015 , ... Intellitec Solutions announced they ... bringing on board their 8th new staff member in 2015. With the potential for ... firm. Intellitec Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and ...
(Date:8/31/2015)... ... , ... Adult & Pediatric Dermatology in Greenwood Village, CO has launched a ... and services available to help them. , The website better showcases the practice ... visitors to view the website seamlessly on any desktop computer, tablet or mobile device. ...
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising ... to help small businesses operate as efficiently and cost effectively as possible, with a ... impact in their first year of operation – and the Charleston business community is ...
Breaking Medicine News(10 mins):Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3
... Recognize ... Heroes, FORT ... to 19 flight attendants who,have administered emergency medical attention by using onboard,defibrillators. ... Fort Worth to celebrate the lives saved and heroic,measures taken during medical ...
... for Local Economy, METAIRIE, La., April 2, 2008 ... and dental practices,worldwide, produces television advertisements for its more ... production of those ads came home to,New Orleans., ... New Orleans, not only,because of the prime locations for ...
... speed up recovery after fractures and breaks simply by removing ... rats suggests that the technique could kick-start rapid self-healing in ... a bone growth hormone., Agnes Vignerys team at Yale University ... thigh-bone of each animal before syringing out the bone marrow. ...
... 2, 2008 Anthem Blue Cross,announced today process ... year. The changes will include reimbursement modifications and ... by the Centers,for Medicare and Medicaid Services (CMS) ... Anthem Blue Cross,s eight million members from,additional payments ...
... The National,Association of Realtors(R) joined U.S. Senators Richard ... Norm Coleman, R-Minn.,as they introduced the Small Business ... program but reiterates the importance of,reforming the U.S. ... A recently conducted 2008 NAR Health Insurance ...
... -- A patient,s willingness to participate in a clinical trial ... interests in the study, unless the amount of money a ... trial, according to a new study by researchers at the ... Johns Hopkins Berman Institute of Bioethics. , We found ...
Cached Medicine News:Health News:American Airlines Honors Flight Attendants at Golden Heart Awards Ceremony 2Health News:OrthoSynetics(TM) Brings Ad Production Home to New Orleans 2Health News:Bones mend faster without marrow 2Health News:Anthem Blue Cross Announces Initiative Aimed at Preventing Serious Medical Errors; Company Committed to Protecting Members' Health and Finances by Not Reimbursing Major Preventable Adverse Events 2Health News:Anthem Blue Cross Announces Initiative Aimed at Preventing Serious Medical Errors; Company Committed to Protecting Members' Health and Finances by Not Reimbursing Major Preventable Adverse Events 3Health News:U.S. Health Care System Must Be Reformed, Say Nine Out of 10 Realtors(R) 2Health News:Knowing doctor's financial interests doesn't deter clinical trial participants 2Health News:Knowing doctor's financial interests doesn't deter clinical trial participants 3
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
2 mm tip....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: